PFIZER INC

PFE

Held by 4 specialist biotech funds

High Convergence

4 funds opened new positions. Next phase3 readout (PhXA41): Feb 1994. Short interest: 2.6% of float.

Drug Manufacturers - GeneralCEO: Albert BourlaIPO: 1972Website ↗

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Catalysts

Phase 3PositiveQ1 1994PhXA41Glaucoma, Open Angle Glaucoma, Ocular HypertensionNCT00751127

Primary: to demonstrate the IOP-reducing effect of PhXA41 is comparable to that of timolol at the end of 6 months of treatment. (6 mos)Enrollment:268/268Sites: 17RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q2 1998Meningococcal CMeningitis, MeningococcalNCT00314041

Primary: Antibody responses to MnCC and concomitant vaccinesEnrollment:Target 240RANDOMIZED, DOUBLE, PREVENTION

Phase 3Q2 1999Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)Encephalitis, Tick-borneNCT00161746

Sites: 7RANDOMIZED, DOUBLE, PREVENTION

Phase 3PositiveQ3 2000Inhaled human insulinDiabetes Mellitus, Type 1NCT00424437

Primary: Primary outcome is 24 week change in baseline in HbA1cEnrollment:Target 320Sites: 36RANDOMIZED, TREATMENT

Phase 2Q1 2002PantoprazolePeptic Ulcer HemorrhageNCT00037570

Enrollment:12/12Sites: 6RANDOMIZED, PREVENTION

Phase 3Q1 2003PN-152,243)/PN-196,444SarcomaNCT00038311

Primary: To evaluate the effectiveness of intravenous rhTPO versus placebo in reducing the cumulative proportion of patients who experience severe chemotherapy induced thrombocytopenia.Enrollment:Target 120Sites: 6RANDOMIZED, DOUBLE, PREVENTION

Phase 3Q3 2003placeboLaparoscopic Cholecystectomy, PainNCT00661635

Primary: Patient's Global Evaluation of Study Medication (Day 2 and Day 3)Enrollment:490/490Sites: 65RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q1 2004clarithromycin extended release (ER)PneumoniaNCT00643227

Primary: sponsor assessment of clinical response (clinical cure rate) in the Clinical Per Protocol population (Test of Cure (TOC) visit (Day 14-21))Enrollment:504/504Sites: 72RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ3 2004ReFacto AFHemophilia ANCT00037544

TREATMENT

Phase 2Q4 2004EKB-569Colorectal Neoplasms, Colonic Neoplasms, Rectal NeoplasmsNCT00072748

Enrollment:63/63NON_RANDOMIZED, TREATMENT

Phase 3NegativeQ1 2005SynercidGram-Positive Bacterial InfectionsNCT00240747

Primary: Population pharmacokineticsSites: 6NON_RANDOMIZED, TREATMENT

Phase 3Q1 2005GabapentinTransient InsomniaNCT00667108

Primary: Subjective sleep latency (Hour +8)Enrollment:784/784Sites: 8RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q1 2005ZiprasidoneSchizophrenia, Bipolar Disorder, Schizoaffective DisorderNCT00650611

Primary: Adverse events at Baseline, Day 4, and Weeks 1, 2, 3, 4, 8, 12, 18, and 27. (27 weeks)Enrollment:63/63Sites: 17RANDOMIZED, TREATMENT

Phase 3NegativeQ2 2005Azithromycin/ChloroquineMalaria, FalciparumNCT00084240

Primary: parasite clearanceEnrollment:32/32RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q2 2005Letrozole / Temsirolimus (CCI-779)Breast NeoplasmsNCT00062751

Primary: Percentage of Participants With Objective Response (OR) (Baseline, every 4 cycles (1 cycle is defined as a 14 day duration) up to Cycle 25, then every 6 cycles until disease progression)Enrollment:108/108RANDOMIZED, TREATMENT

Phase 3PositiveQ2 2005PregabalinFibromyalgiaNCT00645398

Primary: Endpoint mean pain score derived from the subject's daily pain diary (Endpoint)Enrollment:751/751Sites: 102RANDOMIZED, DOUBLE, TREATMENT

Phase 2NegativeQ3 2005CP-724,714Breast Neoplasms, Neoplasm MetastasisNCT00102895

Primary: Tumor ResponseEnrollment:Target 25NON_RANDOMIZED, TREATMENT

Phase 3Q4 2005TigecyclineBacterial InfectionsNCT00205816

Primary: responseEnrollment:26/26Sites: 3NON_RANDOMIZED, TREATMENT

Phase 3PositiveQ2 2006varenicline (CP-526,555)Smoking CessationNCT00143325

Primary: Continuous abstinence for the last 4 weeks of varenicline and NRT (Nicotine Replacement Therapy) treatment periodEnrollment:Target 730Sites: 22RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ3 2006pregabalinPartial SeizuresNCT00141258

Primary: Response ratio (RRatio or symmetrized percent change) for all partial seizuresEnrollment:178/178Sites: 5RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2006SomatropinGrowth Hormone Deficiency, Growth RetardationNCT00174278

Primary: The main efficacy variable is the height SDS (SEMPE) before and after treatment.Enrollment:Target 14Sites: 1NON_RANDOMIZED, TREATMENT

Phase 2NegativeQ4 2006GAP-486 (ZP-123)ArrhythmiaNCT00137293

Primary: This study takes place within 24 hours. The measure to determine the effect of the intervention will be the difference in values from the baseline electrophysiology study, and the values obtained after intervention within the test drug.Enrollment:Target 30Sites: 7RANDOMIZED, DOUBLE

Phase 3PositiveQ2 2007Varenicline tartrateSmoking CessationNCT00371813

Primary: To compare 12 weeks of treatment with varenicline 1 mg BID to placebo for smoking cessation, and to evaluate continuous abstinence from smoking for 12 weeks after the treatment period.Enrollment:334/334Sites: 14RANDOMIZED, DOUBLE, TREATMENT

Phase 3NegativeQ3 2007Zoloft (Sertraline)Stress Disorders, Post-TraumaticNCT00150306

Primary: The primary efficacy parameter is the University of California at Los Angeles Post-Traumatic Stress Disorder Index for DSM-IV (UCLA PTSD-I).Enrollment:Target 160Sites: 23RANDOMIZED, DOUBLE, TREATMENT

Phase 2NegativeQ3 2007naproxenOsteoarthritisNCT00418782

Primary: To determine the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of oral multiple doses of CE 224,535 in subjects with OA of the knee (ongoing)Enrollment:212/212Sites: 46RANDOMIZED, DOUBLE, TREATMENT

Phase 2NegativeQ4 2007PPM-204Diabetes MellitusNCT00425919

Primary: Fasting Plasma GlucoseEnrollment:Target 500Sites: 68RANDOMIZED, DOUBLE, TREATMENT

Phase 2NegativeQ1 2008PF-02545920SchizophreniaNCT00570063

Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) at Day 21: Total Score (Baseline (Day 1), Day 21)Enrollment:35/35Sites: 10RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q2 2008Placebo; oralDental PainNCT00663767

Primary: Assess the efficacy of the study drug dosed postoperatively in terms of total pain relief (TOTPAR). (6 hours post-dose)Enrollment:250/250Sites: 2RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2008PF-00734200 30 mg QDDiabetes Mellitus, Type 2NCT00618007

Primary: HbA1c (12 weeks)Enrollment:289/289Sites: 79RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2008VoriconazoleAspergillosisNCT00159822

Primary: Number of Subjects With Successful Global Outcome at 6 Months: Chronic Bronchopulmonary Aspergillosis (at 6 months of treatment)Enrollment:48/48Sites: 18NON_RANDOMIZED, TREATMENT

Phase 3NegativeQ1 2009CP-945,598 Treatment AObesityNCT00375401

Primary: Proportion of subjects with 5% weight loss (1 year)Enrollment:2,536/2,536Sites: 82RANDOMIZED, DOUBLE, TREATMENT

Phase 3NegativeQ1 2009AG-013736Carcinoma, Pancreatic DuctalNCT00471146

Primary: Overall Survival (OS) (Baseline until death or at least 1 year after the randomization of last participant)Enrollment:630/630Sites: 204RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2009PregabalinPain, Postoperative, Hernia, InguinalNCT00551135

Primary: Modified Brief Pain Inventory-Short Form (mBPI-sf): Worst Pain 24 Hours Post Surgery (24 hours post surgery)Enrollment:425/425Sites: 42RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2009SunitinibBreast NeoplasmsNCT00373256

Primary: Progression-Free Survival (PFS) (From date of randomization through Day 1 and every 8 weeks thereafter up to 18 months or death)Enrollment:488/488Sites: 250RANDOMIZED, TREATMENT

Phase 3PositiveQ3 2009tanezumabArthritis, OsteoarthritisNCT00733902

Primary: Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 16: Baseline Observation Carried Forward (BOCF) (Baseline (Day 1), Week 16)Enrollment:697/697Sites: 82RANDOMIZED, DOUBLE, TREATMENT

Phase 2PositiveQ3 2009CP-690,550PsoriasisNCT00678210

Primary: Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score at Week 12 (Week 12)Enrollment:197/197Sites: 44RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q4 2009PF-04383119 (tanezumab)Osteoarthritis, KneeNCT00669409

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) (Day 1 up to Day 92 for tanezumab 10, 25, 50 mcg/kg group and matching placebo group (Part 1, 2); Day 1 up to Day 120 for tanezumab 100 mcg/kg group and matching placebo group (Part 1, 2), 200 mcg/kg group and matching placebo group (Part 1))Enrollment:83/83Sites: 12RANDOMIZED, TRIPLE, TREATMENT

Phase 3PositiveQ1 2010pregabalinDiabetic Neuropathy, PainfulNCT00553280

Primary: Summary of Adverse Events (53 weeks)Enrollment:123/123Sites: 27NON_RANDOMIZED, TREATMENT

Phase 2Q2 2010EXC 001Scar PreventionNCT01037413

Primary: Expert Panel Scar Assessment Score at Week 12 (Part B: Week 12)Enrollment:25/25Sites: 5RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2010placeboSmoking CessationNCT00644969

Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (Baseline up to 30 days after last dose of study treatment or up to Week 16)Enrollment:128/128Sites: 14RANDOMIZED, DOUBLE

Phase 3Q2 2010EsreboxetineFibromyalgiaNCT00796601

Phase 3Q2 2010CelecoxibAnkylosing SpondylitisNCT00762463

Primary: Change From Baseline in Participant's Assessment of Global Pain Intensity at Week 6 (Baseline, Week 6)Enrollment:240/240Sites: 5RANDOMIZED, DOUBLE, TREATMENT

Phase 2NegativeQ3 2010ICA-105665EpilepsyNCT00979004

Primary: Change in photosensitivity response (begin 1 hr post dose for 8 hours)Enrollment:13/13Sites: 3RANDOMIZED, SINGLE, TREATMENT

Phase 3Q4 2010Fragmin/ Dalteparin SodiumDiabetic Foot UlcerNCT00662831

Primary: Number of Participants With Greater Than or Equal to 50 Percent Reduction in Ulcer Surface Area Including Intact Skin Healing (Week 24 [end of treatment (EOT)] or early termination)Enrollment:276/276Sites: 63RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2011Growth Hormone DeficiencyNCT01112865

Primary: Percentage of Dyads (Participant and Caregiver or Parent) and Adult Participants Reporting no Difference or Easier to Use for the New Genotropin Mark VII Injection Pen Compared to the Genotropin Pen® (Month 4)Enrollment:120/120Sites: 23RANDOMIZED, TREATMENT

Phase 2Q4 2011AG-013736Carcinoma, Non-Small-Cell Lung (NSCLC)NCT00735904

Primary: Percentage of Participants With Objective Response (OR) (Baseline until disease progression or discontinuation from the study due to any cause, assessed every 6 weeks during chemotherapy phase and every 8 weeks during single agent phase up to final study visit (Week 78))Enrollment:38/38Sites: 10NA, TREATMENT

Phase 3Q1 2012pregabalin (Lyrica)Diabetic Neuropathy, PainfulNCT01057693

Primary: Change From Single-Blind Baseline in Mean Pain Score at Week 19 During Double-Blind Phase (SB Baseline, Week 19 (DB Phase))Enrollment:633/633Sites: 172RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3NegativeQ3 2012PlaceboPain, PerioperativeNCT00905437

Phase 2Q1 2013PlaceboDiabetes Mellitus, Type 2NCT01517373

Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 12 (Baseline (Day 1), Week 12)Enrollment:304/304Sites: 53RANDOMIZED, TRIPLE, TREATMENT

Phase 3PositiveQ1 2013CP-690,550PsoriasisNCT01186744

Phase 3PositiveQ2 2013CP-690,550PsoriasisNCT01276639

Primary: Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 16 (Week 16)Enrollment:901/901Sites: 74RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ4 2013treatmentNon Squamous Lung CancerNCT01154140

Primary: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months))Enrollment:343/343Sites: 249RANDOMIZED, TREATMENT

Phase 2NegativeQ4 2013PF-03049423Ischemic StrokeNCT01208233

Primary: Number of Participants With Any Abnormal Laboratory Test Results (Part 1* and 2) (Day 1 (Baseline) up to Day 90)Enrollment:181/181Sites: 70RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q1 2014MEK162BRAF or NRAS Mutant Metastatic MelanomaNCT01320085

Primary: Percentage of Participants With Objective Response (OR) (From date of randomization or date of start of treatment until date of first documentation of PD or death due to any cause, whichever occurred first (maximum duration of up to 33 months))Enrollment:183/183Sites: 25NON_RANDOMIZED, TREATMENT

Phase 3PositiveQ2 2014PregabalinDiabetic Neuropathy, PainfulNCT01332149

Primary: Baseline Mean Pain Score (Baseline)Enrollment:626/626Sites: 30RANDOMIZED, DOUBLE, TREATMENT

Phase 2Jul 6, 2015SunitinibAdvanced Rare TumoursNCT01396408

Primary: Objective Response (Every 4 weeks)Enrollment:137/137Sites: 17NON_RANDOMIZED, TREATMENT

Phase 3PositiveQ1 2016PD-0332991Breast NeoplasmsNCT01740427

Primary: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization date to date of first documentation of progression or death (up to approximately 2.5 years))Enrollment:666/666Sites: 305RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q1 2016PF-04236921Crohn's DiseaseNCT01345318

Primary: Number of Participants With On-Treatment Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs (Baseline up to Week 48)Enrollment:191/191Sites: 127NON_RANDOMIZED, TREATMENT

Phase 3NegativeQ2 2016CP-690,550PsoriasisNCT01163253

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) (Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months))Enrollment:2,867/2,867Sites: 323NA, TREATMENT

Phase 2Q3 2016Staphylococcus aureus 4-antigen vaccineStaphylococcal InfectionsNCT02492958

Primary: Percentage of Participants With At Least 1 Local Reaction Within 14 Days of Vaccination (Day 1 up to Day 14)Enrollment:136/136Sites: 2RANDOMIZED, QUADRUPLE, OTHER

Phase 2PositiveQ1 2017Bivalent rLP2086 VaccineMENINGOCOCCAL INFECTIONNCT02531698

Primary: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >= Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Neisseria Meningitidis Serogroup B (MnB) Test Strains 1 Month After Vaccination 3 (1 month after Vaccination 3)Enrollment:400/400Sites: 15RANDOMIZED, TRIPLE, PREVENTION

Phase 2Q3 2017rLP2086 vaccineMeningococcal B DiseaseNCT02534935

Phase 3Q1 2018RimegepantMigraine, With or Without AuraNCT03237845

Primary: Percentage of Participants With Freedom From Pain at 2 Hours Post-dose (2 Hours post-dose)Enrollment:1,499/1,499Sites: 50RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q2 2018Moroctocog alfa (AF-CC)Hemophilia ANCT00543439

Primary: Mean Annualized Bleed Rate (ABR) by Treatment: On Demand Cohort (Day 1 up to Month 6 (OD Cohort, OD Therapy, Period 1); Month 7 up to Month 18 (OD Cohort, RP 25 IU/kg, Period 2))Enrollment:66/66Sites: 28RANDOMIZED, TREATMENT

Phase 2Q2 2018Crisaborole ointment 2% BIDDermatitis, AtopicNCT03233529

Phase 2Q1 2019PlaceboNonalcoholic Fatty Liver Disease, Nonalcoholic SteatohepatitisNCT03248882

Primary: Percent Change From Baseline in Liver Fat by Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI- PDFF) at Week 16 (Baseline (between Day -14 and Day 1), Week 16)Enrollment:305/305Sites: 140RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ4 201920vPnCPneumococcal DiseaseNCT03828617

Primary: Percentage of Participants With Local Reactions Within 10 Days After Vaccination (Within 10 days after vaccination)Enrollment:1,710/1,710Sites: 21RANDOMIZED, DOUBLE, PREVENTION

Phase 3NegativeQ4 2019AvelumabSquamous Cell Carcinoma of the Head and NeckNCT02952586

Primary: Progression-free Survival (PFS) Per Modified Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1) as Assessed by Investigator (From randomization until documented PD or death, censored date, whichever occurred first (up to 37 months))Enrollment:697/697Sites: 316RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ1 2020LorlatinibCarcinoma, Non-Small-Cell LungNCT03052608

Primary: Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) Assessment (From time of Study Start up to 33 months)Enrollment:296/296Sites: 166RANDOMIZED, TREATMENT

Phase 3Q2 2020PlaceboAtopic DermatitisNCT03796676

Primary: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of 'Clear' (0) or 'Almost Clear' (1) and ≥2 Points Improvement From Baseline at Week 12 (Baseline to Week 12)Enrollment:287/287Sites: 136RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q2 2020PF-06700841Atopic DermatitisNCT03903822

Primary: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 6: Multiple Imputation (Baseline, Week 6)Enrollment:292/292Sites: 76RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Jun 1, 2020Neoadjuvant tamoxifen + goserelin (premenopausal women)Breast CancerNCT02624973

Primary: Predictive and prognostic value of mutations in 300 cancer-related genes assessed in breast cancer tissue by next generation sequencing before starting neoadjuvant therapy. (Ten years)Enrollment:200/200Sites: 7NON_RANDOMIZED, BASIC_SCIENCE

Phase 2PositiveQ3 2020TalazoparibProstate CancerNCT03148795

Primary: Best Objective Response Rate (ORR) (From first dose of study drug to best overall soft tissue response CR or PR (maximum duration of 25 months))Enrollment:128/128Sites: 120NA, TREATMENT

Phase 3Q4 2020PalbociclibBreast CancerNCT02513394

Primary: Invasive Disease Free Survival (iDFS) (4 years)Enrollment:5,796/5,796Sites: 437RANDOMIZED, TREATMENT

Phase 3Q1 2021etanerceptJuvenile Idiopahtic ArthritisNCT01421069

Primary: Number of Participants With Malignancy: All Periods of Parent and Extension Study (First dose of study medication in parent study up to 96 months in the extension study, for a maximum duration of 118 months (22 months of parent study and 96 months of extension study))Enrollment:109/109Sites: 35NA, TREATMENT

Phase 2Apr 13, 2021PD0332991Breast NeoplasmsNCT01723774

Primary: Number of Participants With Complete Cell Cycle Arrest at Cycle 1 Day 15 (PIK3CA Wild Type Cohort Only) (At cycle 1 day 15 (2 weeks))Enrollment:84/84Sites: 4NON_RANDOMIZED, TREATMENT

Phase 3PositiveQ4 2021RimegepantAcute MigraineNCT04574362

Phase 2Feb 15, 2022PalbociclibHead and Neck Squamous Cell CarcinomaNCT03389477

Primary: Tumor Response Rate of Newly Diagnosed p16INK4a Negative, HPV-unrelated HNSCC to Neoadjuvant Palbociclib Monotherapy (2 cycles (56 days))Enrollment:26/26Sites: 1NON_RANDOMIZED, TREATMENT

Phase 2Q1 2022LetrozoleBreast CancerNCT02764541

Primary: Difference in Anti-proliferative Activity of Patients Given Letrozole Versus Tamoxifen During the Window Phase (baseline to day 15)Enrollment:195/195Sites: 11RANDOMIZED, TREATMENT

Phase 2Q1 2022PF-06801591Advanced Malignancies, Non-small-cell Lung CancerNCT04181788

Primary: Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT) (Phase 1b: at the end of cycle 1 (28 days) for the PF-06801591 300 mg SC Q4W arms, and (42 days) for the PF-06801591 600 mg SC Q6W arms)Enrollment:155/155Sites: 49RANDOMIZED, TREATMENT

Phase 2Apr 29, 2022PalbociclibProstate CancerNCT02905318

Primary: Clinical benefit rate estimated by proportion of evaluable patients who had CR, PR or SD as their best response to treatment (36 months)Enrollment:19/19Sites: 7NA, TREATMENT

Phase 2Q2 2022Elranatamab (PF-06863135)Multiple MyelomaNCT04649359

Primary: Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) as Per International Myeloma Working Group (IMWG) Criteria (From date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurred first (up to approximately 16 months))Enrollment:187/187Sites: 40NON_RANDOMIZED, TREATMENT

Phase 2Sep 30, 2022TanezumabSchwannomatosis, PainNCT04163419

Primary: Change in pain level (8 weeks)Enrollment:9/9Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2022Talazoparib with enzalutamidem CRPCNCT03395197

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Occuring Within the First 66 Days of Dosing - Part 1 (Post dose on Day 1 up to Day 66 in Part 1)Enrollment:1,054/1,054Sites: 368RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2022PF-06838435/ fidanacogene elaparvovecHemophilia BNCT03861273

Primary: Annualized Bleeding Rate (ABR) for Total Bleeds (Treated and Untreated) From Week 12 to Month 15 (Pre-infusion period: minimum of 6 months through first dose of current study, an average of 1.31 years (FIX Prophylaxis arm); Week 12 to Month 15 post infusion in current study (PF-06838435 arm))Enrollment:51/51Sites: 67NON_RANDOMIZED, TREATMENT

Phase 2Dec 31, 2022PalbociclibMetastatic Breast CancerNCT03147287

Primary: Progression-Free Survival (PFS), According to RECIST v1.1 Criteria (Investigator Assessment) (Tumor were assessed every 8 weeks until 24 weeks, then every 12 weeks. The median PFS follow-up time at database lock was 12.1 months (range 1 day to 50.1 months).)Enrollment:220/220Sites: 22RANDOMIZED, TREATMENT

Phase 3Q1 2023EnzalutamideHormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the ProstateNCT02319837

Primary: Metastasis-free Survival (MFS) Compared Between Enzalutamide Plus Leuprolide and Placebo Plus Leuprolide (From randomization until radiographic progression or death without radiographic progression, whichever occurred first (up to Month 98 when at least 197 MFS events occurred among the 3 treatment groups))Enrollment:1,068/1,068Sites: 255RANDOMIZED, TREATMENT

Phase 2Apr 7, 2023EnzalutamideProstate CancerNCT03809000

Primary: Percentage of Participants Alive Without Progression (Progression-Free Survival) (From randomization to first failure or last known follow-up. Median follow-up time at the time of analysis was 33.1 months. The 1- and 2-year estimates are reported.)Enrollment:188/188Sites: 108RANDOMIZED, TREATMENT

Phase 2May 1, 2023VinorelbineBreast CancerNCT03414658

Primary: Progression Free Survival (2 years)Enrollment:100/100Sites: 17RANDOMIZED, TREATMENT

Phase 3Q2 2023tucatinibHER2-positive Breast CancerNCT03975647

Primary: Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment (From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months))Enrollment:466/466Sites: 486RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2023TucatinibBreast CancerNCT04721977

Primary: Confirmed Objective Response Rate(cORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Determined by Independent Central Review (ICR): Japanese Participants (From date of first dose until first documented disease progression or start of new anticancer therapy, whichever occurred first (maximum up to 17.8 months))Enrollment:66/66Sites: 28NA, TREATMENT

Phase 2Jul 28, 2023Talazoparib + AvelumabUrothelial CarcinomaNCT04678362

Primary: The progression-free survival (7 months)Enrollment:Target 50Sites: 14NA, TREATMENT

Phase 2Sep 26, 2023Gemtuzumab Ozogamicin (GO)Acute Myeloid LeukemiaNCT03374332

Primary: Response Rate (Post infusion for a total of 2 years.)Enrollment:11/11Sites: 1NON_RANDOMIZED, TREATMENT

Phase 2Q3 2023nirmatrelvirCOVID-19NCT05567952

Phase 2Q4 2023tucatinibUterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract NeoplasmsNCT04579380

Primary: Confirmed Objective Response Rate (cORR) as Assessed by Investigator (From the first dose of study treatment until the first documented CR or PR on or before the first documented PD or new anti-cancer therapies or death, whichever occurred first (up to 28.3 months))Enrollment:217/217Sites: 106NA, TREATMENT

Phase 2Nov 15, 2023AvelumabMetastatic Endometrial CancerNCT02912572

Primary: Objective Response Rate (Up to 39 months)Enrollment:106/106Sites: 4NON_RANDOMIZED, TREATMENT

Phase 2Dec 26, 2023LorlatinibAdvanced or Metastatic ROS1-Positive Non-Small Cell Lung CancerNCT05297890

Primary: Objective Response Rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per Independent Central Radiology (ICR) assessment (From the date of first dose of first subject to 6 months after the first dose of last subject, assessed up to approximately 19 months)Enrollment:70/70Sites: 31NA, TREATMENT

Phase 2May 7, 2024Abrocitinib 200 mgGranuloma AnnulareNCT05650736

Phase 3Q2 2024Duchenne Muscular DystrophyNCT04281485

Phase 3Q2 2024PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene TherapyHemophilia ANCT04370054

Phase 3Jun 25, 2024PF-06651600Alopecia AreataNCT04006457

Phase 2Jun 30, 2024GlasdegibAcute Myelogenous Leukemia (AML) Due to Therapy, Acute Myeloid Leukemia With Myelodysplasia-Related ChangesNCT04231851

Phase 2Q3 2024GedatolisibTNBC - Triple-Negative Breast CancerNCT03911973

Phase 2Q3 2024tucatinibColorectal Carcinoma, Gastric Adenocarcinoma, GEJ AdenocarcinomaNCT04430738

Phase 2Q3 2024PalbociclibEwing Sarcoma, Solid Tumors, Rhabdoid TumorNCT03709680

Phase 2Q3 2024BNT162b2 (Omi XBB.1.5)/RIVInfluenza, Human, SARS-Co V-2 Infection, COVID-19NCT06237049

Phase 2Sep 13, 2024ARV-471Breast CancerNCT04072952

Phase 2Sep 18, 2024TG4001HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Anal Squamous Cell CarcinomaNCT03260023

Phase 3Oct 15, 2024palbociclibHER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast CancerNCT02947685

Phase 3Q4 2024PF-06801591Non-muscle Invasive Bladder CancerNCT04165317

Phase 2Q4 2024CrizotinibNon-squamous Non-small-cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, ROS1 Gene RearrangementNCT04084717

Phase 3Q1 2025ARV-471Advanced Breast CancerNCT05654623

Phase 2NegativeQ1 2025Elranatamab + NirogacestatMultiple MyelomaNCT05090566

Phase 3Feb 28, 2025EtanerceptOligoarthritis, Juvenile, Polyarthritis, Juvenile, Rheumatoid Factor NegativeNCT03728478

Phase 3PositiveQ2 2025RSVpreF vaccineRespiratory Syncytial VirusNCT06325657

Phase 3Jun 16, 2025Tofacitinib 10mgGlioblastomaNCT05326464

Phase 2Q3 2025MET097Obesity, Overweight or ObesityNCT06712836

Phase 2Aug 1, 2025SasanlimabUrothelial Carcinoma BladderNCT05241340

Phase 3Q3 2025TucatinibHER2 Positive Breast CancerNCT05132582

Phase 2Q3 2025vepdegestrantBreast CancerNCT06206837

Phase 2Sep 17, 2025VoxelotorSickle Cell DiseaseNCT06023199

Phase 3Q3 2025PalbociclibBreast NeoplasmsNCT03423199

Phase 2Q3 2025AZD4547Non-Small Cell Lung Cancer, Carcinoma, Squamous Cell, AdenocarcinomaNCT02664935

Phase 3Q4 2025EncorafenibNeoplasmsNCT04607421

Phase 2Q4 2025MET097Obesity, Overweight or ObesityNCT06973720

Phase 3Q4 2025VLA15Lyme DiseaseNCT05477524

Phase 2Dec 31, 2025OnivydeRecurrent Solid Tumor, Recurrent Ewing Sarcoma, Recurrent HepatoblastomaNCT04901702

Phase 2Dec 31, 2025RitlecitinibCeliac DiseaseNCT05636293

Phase 2Q4 2025Irinotecan + CarboplatinMetastatic Breast CancerNCT00248287

Phase 3Q4 2025SasanlimabNSCLCNCT06218069

Phase 2Jan 2, 2026MET097 InjectionObesity in Diabetes, Type 2 Diabetes Mellitus (T2DM)NCT06897202

Phase 3Q1 2026Brentuximab vedotinDiffuse Large B-cell LymphomaNCT04404283

Phase 2Q1 2026PF-07220060 CDK4 inhibitorAdvanced or Metastatic Breast CancerNCT06105632

Phase 3Q1 2026EncorafenibMelanomaNCT04657991

Phase 3Jan 27, 2026Palbociclib 125mgBreast Cancer RecurrentNCT03820830

Phase 3Feb 1, 2026KetamineChronic Daily HeadacheNCT05306899

Phase 2Q1 2026brentuximab vedotinMelanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and NeckNCT04609566

Phase 2Feb 14, 2026Brentuximab vedotinDiffuse Cutaneous Systemic SclerosisNCT05149768

Phase 3Feb 15, 202640 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetateEndometriosisNCT06439524

Phase 3Q1 2026talazoparib plus enzalutamideProstate CancerNCT04821622

Phase 3Q1 2026sigvotatug vedotinCarcinoma, Non-Small-Cell LungNCT06012435

Phase 2Q1 2026tisotumab vedotinColorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic CancerNCT03485209

Phase 2Mar 30, 2026PalbociclibMantle Cell Lymphoma, B Cell LymphomaNCT03478514

Phase 2Mar 30, 2026AbrocitinibPost-COVID Condition, Fatigue SymptomNCT06597396

Phase 2Mar 31, 2026DacomitinibNSCLC Stage IIIB, NSCLC Stage IIIC, NSCLC Stage IVNCT04027647

Phase 2Q1 2026TalazoparibBreast CancerNCT03964532

Phase 2NegativeMar 31, 2026Tisotumab VedotinCervical CancerNCT03786081

Phase 2Apr 1, 2026AxitinibMetastatic Renal Cell CarcinomaNCT05817903

Phase 3Q2 2026tucatinibColorectal NeoplasmsNCT05253651

Phase 2NegativeQ2 2026maplirpacept (PF-07901801)Diffuse Large B-Cell LymphomaNCT05896163

Phase 2Q2 2026MET233Obesity and OverweightNCT07022977

Phase 3Apr 17, 2026DexmedetomidineDelirium, Critical Illness, Sedation ComplicationNCT04801589

Phase 3Q2 2026ElranatamabMultiple MyelomaNCT05020236

Phase 2Q2 2026TrastuzumabBrain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast CancerNCT05323955

Phase 2Q2 2026vepdegestrantBreast CancerNCT06125522

Phase 3May 5, 2026BNT162b2 (2025/2026 recommended SARS-CoV-2 strain)COVID-19, SARS-COV-2 InfectionNCT07069309

Phase 2Q2 2026Multivalent Pneumococcal Vaccine - Formulation 1Pneumococcal DiseaseNCT06182124

Phase 2Q2 2026disitamab vedotinCarcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial NeoplasmsNCT06003231

Phase 2Q2 2026EncorafenibMetastatic Colorectal CancerNCT05217446

Phase 3Jun 16, 2026Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram doseSARS-Co V-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19NCT05543616

Phase 2Jun 30, 2026anastrozoleFemale Breast Carcinoma, Breast CancerNCT02942355

Phase 2Q2 2026PalbociclibMetastatic Breast CancerNCT02738866

Phase 2Jun 30, 2026PalbociclibBreast Cancer Stage II, Breast Cancer Stage IIINCT03609047

Phase 2Q2 2026TalazoparibBreast CancerNCT04039230

Phase 2Jun 30, 2026Abrocitinib 200 MG Oral TabletDiabetes Mellitus, Type 1NCT05743244

Phase 3Q2 2026disitamab vedotinUrothelial CarcinomaNCT05911295

Phase 2Jun 30, 2026Anti-OX40 Antibody PF-04518600Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast CancerNCT03971409

Phase 3Q3 2026PF-06821497Metastatic Castrate Resistant Prostate Cancer (m CRPC)NCT06551324

Phase 3Q3 2026nirmatrelvirCOVID-19NCT05261139

Phase 3Jul 31, 2026BNT162b2 VaccineCOVID-19, SARS-COV-2 InfectionNCT07300839

Phase 3Jul 31, 2026BNT162b2 (2025/2026 formulation)COVID-19, SARS-COV-2 InfectionNCT07222384

Phase 2Aug 1, 2026ElranatamabRefractory Multiple Myeloma, Relapse Multiple Myeloma, Multiple MyelomaNCT06138275

Phase 2Q3 2026ATM-AVIGram-negative Bacterial InfectionsNCT05639647

Phase 2Aug 20, 2026IpilimumabMelanomaNCT04996823

Phase 2Q3 2026PF-07220060 + PF-07104091 combination dose escalationBreast Cancer, Solid TumorsNCT05262400

Phase 3Q3 2026ElranatamabMultiple MyelomaNCT06152575

Phase 3Q3 2026RSVpreFRespiratory Syncytial Virus (RSV)NCT07543380

Phase 2Aug 31, 2026TalazoparibBreast CancerNCT03990896

Phase 2Sep 1, 2026PalbociclibMetastatic Malignant Neoplasm to Brain, Recurrent Brain Metastases, Progressive Brain MetastasesNCT02896335

Phase 2Q3 2026ARV-471Breast CancerNCT05548127

Phase 2Q3 2026PF-07868489Pulmonary Arterial HypertensionNCT06137742

Phase 2Q3 2026PF-07220060Liposarcoma, Prostate Cancer, Breast NeoplasmsNCT04557449

Phase 2Sep 30, 2026AvelumabBreast CancerNCT03573648

Phase 3Q3 2026AvelumabAdvanced Malignancies, NSCLC, Ovarian CancerNCT05059522

Phase 2Q3 2026Ipatasertib 300mgMetastatic Breast Cancer, ER+ Breast Cancer, Advanced Breast CancerNCT04920708

Phase 2Oct 1, 2026SasanlimabMetastatic Renal Cell Carcinoma, Metastatic Renal Cancer, Renal Cell CarcinomaNCT07123090

Phase 2Oct 1, 2026TalazoparibRecurrent Extensive Stage Small Cell Lung Carcinoma, Refractory Extensive Stage Small Cell Lung CarcinomaNCT03672773

Phase 2Oct 1, 2026Atezolizumab - 28 Day CycleEndometrial CancerNCT04486352

Phase 3Q4 2026RimegepantMigraineNCT06616194

Phase 2Q4 2026PF-07275315Atopic DermatitisNCT05995964

Phase 3Q4 2026RimegepantMenstrual MigraineNCT06641466

Phase 2Q4 2026PalbociclibMetastatic Breast Cancer (MBC)NCT02605486

Phase 2Q4 2026OnvansertibMetastatic Colorectal Cancer, CRC, KRAS/NRAS MutationNCT06106308

Phase 2Dec 1, 2026elranatamabRelapsed Refractory Multiple Myeloma (RRMM), Relapsed Refractory Multiple MyelomaNCT06832865

Phase 2Dec 1, 2026ElranatamabMultiple MyelomaNCT06015542

Phase 3Q4 2026PF-06821497Metastatic Castration-Resistant Prostate CancerNCT06629779

Phase 3Q4 2026VLA15Lyme DiseaseNCT07500506

Phase 2Dec 4, 2026SunitinibRenal Cell CarcinomaNCT00715442

Phase 3Q4 2026ibuzatrelvirCOVID-19 InfectionNCT07013474

Phase 2Q4 2026disitamab vedotinUrothelial CarcinomaNCT04879329

Phase 2Q4 2026Ritlecitinib 50 mgChronic Spontaneous UrticariaNCT07219615

Phase 2Q4 2026ARV-471Breast CancerNCT05573555

Phase 3Q4 2026Vepdegestrant (ARV-471/PF-07850327)Breast CancerNCT05909397

Phase 2Q4 2026PF-07104091 monotherapy dose escalationSmall Cell Lung Cancer, Ovarian Cancer, Breast CancerNCT04553133

Phase 2Dec 31, 2026GemcitabineHodgkin LymphomaNCT05180097

Phase 2Q4 2026Elranatamab injectionRefractory Multiple MyelomaNCT06421675

Phase 2Dec 31, 2026Gemtuzumab OzogamicinAcute Myeloid LeukemiaNCT03737955

Phase 2Dec 31, 2026OlaparibLymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsNCT03297606

Phase 2Dec 31, 2026SunitinibCiliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris MelanomaNCT02068586

Phase 2Q4 2026PalbociclibBreast Cancer, Head and Neck CancerNCT05226871

Phase 2Dec 31, 2026Tucatinib 150 MGHER2-positive Breast Cancer, LMDNCT06016387

Phase 3Q1 2027RSVpreFLower Respiratory Tract IllnessNCT05035212

Phase 2Q1 2027MET233 and MET097Obesity and Obesity-related Medical ConditionsNCT06924320

Phase 2Jan 30, 2027Brentuximab vedotinMycosis FungoidesNCT05357794

Phase 2Q1 2027BinimetinibMetastatic Uveal MelanomaNCT05170334

Phase 2Q1 2027AxitinibPheochromocytoma, ParagangliomaNCT03839498

Phase 2Q1 2027RitlecitinibHidradenitis SuppurativaNCT07228390

Phase 2Q1 2027PF-07275315AsthmaNCT06977581

Phase 3Q1 2027RitlecitinibVitiligoNCT06163326

Phase 3Q2 2027tofacitinibUlcerative ColitisNCT04624230

Phase 3Q2 2027Ritlecitinib higher doseSevere Alopecia AreataNCT07029711

Phase 2Q2 2027Part A: ATM-AVI Single Dose, Cohorts 1-4Gram-negative Bacterial InfectionNCT06462235

Phase 2Q2 2027MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GOAcute Myeloid LeukemiaNCT04385290

Phase 2Q2 2027PG4Pneumococcal DiseaseNCT06524414

Phase 3Q2 2027AbrocitinibEczemaNCT06807268

Phase 2May 31, 2027DelamanidTuberculosis, Multidrug-ResistantNCT03828201

Phase 2Q2 2027Nivolumab and/or IpilimumabMucosal MelanomaNCT05384496

Phase 2Q2 2027Vaccine Candidate #1Healthy AdultsNCT07431853

Phase 2Jul 1, 2027RelugolixProstate Cancer, Prostatic NeoplasmsNCT05765500

Phase 3Q3 2027PF-07248144Breast CancerNCT07062965

Phase 3Q3 2027PF-06823859MyositisNCT05895786

Phase 3Q3 2027RitlecitinibStable Nonsegmental Vitiligo, Active Nonsegmental VitiligoNCT06072183

Phase 2Q3 2027HCQBreast CancerNCT04841148

Phase 2Q3 2027ElranatamabSmoldering Multiple MyelomaNCT06183489

Phase 3Q3 2027ElranatamabMultiple MyelomaNCT05317416

Phase 2Q3 2027RitlecitinibKeloidNCT06373458

Phase 2Sep 1, 2027Palbociclib 125Mg TabER+ Breast Cancer, HER2-negative Breast CancerNCT04985266

Phase 3Q3 2027MET097Obesity and OverweightNCT07311850

Phase 2Q3 2027PanitumumabCancer, Tumors, NeoplasmNCT02925234

Phase 3Q4 2027ibuzatrelvirCOVID-19 SARS-Co V-2 InfectionNCT06679140

Phase 3Q4 2027PF-08653944Obesity, Overweight and/or Obesity, OverweightNCT07400653

Phase 2Q4 2027PF-08634404Carcinoma, Hepatocellular, Hepatocellular Cancer, Hepatocellular CarcinomaNCT07227012

Phase 2Q4 2027Disitamab vedotinBreast Cancer, Breast NeoplasmsNCT06966453

Phase 2Q4 2027PF-08634404Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal CancerNCT07227415

Phase 2Q4 2027PlaceboHeart FailureNCT06991257

Phase 3Q4 2027DazukibartDermatomyositis, PolymyositisNCT06698796

Phase 2Q4 2027TucatinibBreast CancerNCT05748834

Phase 2Nov 30, 2027Enfortumab VedotinMuscle-invasive Bladder CancerNCT07475806

Phase 3Q4 2027PG4Pneumococcal DiseaseNCT07660198

Phase 2Q4 2027PF-08634404Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial CarcinomaNCT07421700

Phase 2Dec 31, 2027LHRH AgonistProstate CancerNCT00329043

Phase 2Dec 31, 2027LeuprolideProstate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8NCT06330805

Phase 3Dec 31, 2027Axitinib plus ToripalimabRenal Cell Carcinoma, NeoadjuvantNCT05738694

Phase 3Q4 2027SomatrogonISS, SGANCT07226089

Phase 2Dec 31, 2027PalbociclibLymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsNCT02693535

Phase 2Dec 31, 2027Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant SugemalimabLung Cancer (NSCLC)NCT06987734

Phase 3Q1 2028ponsegromabCachexia, Metastatic Pancreatic Ductal AdenocarcinomaNCT06989437

Phase 3Q1 2028VLA15Lyme BorreliosisNCT07226882

Phase 2Q1 2028PF-08049820Atopic Dermatitis, Eczema, AtopicNCT07216027

Phase 3Q1 2028RSVpreFRSV InfectionNCT06866405

Phase 3Feb 28, 2028PalbociclibHPV-unrelated Head and Neck Squamous Cell CarcinomaNCT04966481

Phase 2Q1 2028Relugolix 120 MG [Orgovyx]Prostate CancerNCT06111781

Phase 3Q1 2028PF-08046054Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung CarcinomaNCT07144280

Phase 3Q1 2028Ritlecitinib 100 mgAlopecia AreataNCT06873945

Phase 2Q1 2028PF-08634404Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung CancerNCT07476287

Phase 2Q1 2028Venetoclax; RituximabWaldenstrom Macroglobulinemia, Treatment NaiveNCT05099471

Phase 3Q2 2028PF-08653944Obesity, Overweight and/or Obesity, OverweightNCT07595549

Phase 2May 9, 2028TucatinibMetastatic Breast CancerNCT05892068

Phase 2Q2 2028DexamethasoneAcute Lymphoblastic Leukemia, Lymphoblastic LymphomaNCT06533748

Phase 2Jul 10, 2028AML, Leukaemia (Acute Myeloid)NCT05199051

Phase 2Q3 2028PF-07868489Pulmonary HypertensionNCT07073820

Phase 2Q3 2028BosutinibPhiladelphia Chromosome Positive CML, Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous LeukemiaNCT04258943

Phase 2Q3 2028PF-06835375Primary Immune ThrombocytopeniaNCT05070845

Phase 2Q3 2028PF-08634404Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC)NCT07489066

Phase 3Q3 2028Sigvotatug VedotinNon-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)NCT06758401

Phase 3Q3 2028marstacimabHemophilia A, Hemophilia BNCT05611801

Phase 3Q3 2028MevrometostatMetastatic Castration Sensitive Prostate Cancer (m CSPC), Hormone Sensitive Prostate Cancer, Prostate CancerNCT07028853

Phase 3Q3 2028RimegepantPreventive Treatment of MigraineNCT07729462

Phase 3Q4 2028Multivalent Group B streptococcus vaccineHealthyNCT07160244

Phase 2Nov 18, 2028prifetrastat monotherapy for 15 days then combination with fulvestrantMetastatic (Stage IV) MelanomaNCT07340619

Phase 2Nov 30, 2028DarolutamideProstate Cancer, Advanced Prostate Cancer, Hormone Sensitive Prostate CancerNCT06463457

Phase 2Dec 7, 2028Tucatinib (ONT-380)Metastatic Breast Cancer ( HER2 Negative), Unresectable Breast CancerNCT07193394

Phase 3Q4 2028C.difficile vaccineClostridioides Difficile Associated DiseaseNCT07282665

Phase 2Dec 31, 2028ElranatamabPhase 2, Radiotherapy-Induced Immune Priming, ElranatamabNCT07382739

Phase 3Q1 2029PF-07220060Breast CancerNCT06760637

Phase 3Q1 2029Rimegepant/BHV3000Pediatric MigraineNCT04649242

Phase 2Q1 2029Blinatumomab InjectionB-cell Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukemia, Adult, B-ALLNCT07313852

Phase 3Q1 2029PF-08634404Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell LungNCT07222566

Phase 2Q1 2029PF-08634404Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung CancerNCT07227298

Phase 2Q1 2029Talazoparib with enzalutamideProstate Cancer (Adenocarcinoma), m CRPC (Metastatic Castration-resistant Prostate Cancer)NCT06844383

Phase 2Q2 2029ElranatamabMyelomaNCT06947083

Phase 2Apr 30, 2029AlectinibCancer, Tumors, NeoplasmsNCT04341181

Phase 2Q2 2029PF-06838435 (formerly SPK-9001)Hemophilia BNCT03307980

Phase 3Q2 2029LY4064809Breast Neoplasms, Neoplasm MetastasisNCT07174336

Phase 3Q2 2029tilrekimigAsthmaNCT07772921

Phase 2Q2 2029EtrasimodUlcerative ColitisNCT05287126

Phase 3Q2 2029EtrasimodUlcerative ColitisNCT03950232

Phase 3Jul 1, 2029Abiraterone AcetateRecurrent Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8NCT06650579

Phase 2Q3 2029PF-07248144Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung CancerNCT04606446

Phase 2Q3 2029disitamab vedotinBreast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast NeoplasmsNCT06157892

Phase 2Jul 31, 2029enzalutamideProstate CancerNCT02960022

Phase 2Aug 27, 2029Elranatamab-bcmmMultiple MyelomaNCT07454382

Phase 2Dec 31, 2029ElranatamabMultiple Myeloma, Post-transplant MRD-guided Maintenance Therapy, Pre-transplant PurgingNCT06207799

Phase 2Feb 6, 2030etrasimodPouchitisNCT07486921

Phase 3Q1 2030PF-08634404Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System NeoplasmsNCT07222800

Phase 3Q2 2030PF-08634404Small Cell Lung Cancer (SCLC)NCT07226999

Phase 3Q2 2030Ritlecitinib higher doseSevere Alopecia AreataNCT07029828

Phase 2Jul 15, 2030Brentuximab VedotinHodgkin Lymphoma, Advanced Hodgkin LymphomaNCT07002216

Phase 3Q3 2030Rimegepant (PF-07899801)Acute Treatment of MigraineNCT04743141

Phase 3Q3 2030PF-06741086Hemophilia A, Hemophilia BNCT05145127

Phase 2Q3 2030EtrasimodColitis, UlcerativeNCT07470879

Phase 2Sep 30, 2030CapecitabineMetastatic Breast CancerNCT03424005

Phase 2Sep 30, 2030LenalidomideMultiple MyelomaNCT06997081

Phase 3Q4 2030ElranatamabMultiple MyelomaNCT05623020

Phase 3Q4 2030PF-07275315 dose 1Moderate to Severe Chronic Obstructive Pulmonary DiseaseNCT07363694

Phase 2Dec 1, 2030Elranatamab (PF-06863135)Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant IneligibleNCT07247097

Phase 3Q4 2030OsivelotorSickle Cell DiseaseNCT05431088

Phase 2Q2 2031C. difficile vaccine (previously studied formulation).Clostridoides Difficile Associated DiseaseNCT05805826

Phase 3Q3 2031PF-08634404Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction CancerNCT07392892

Phase 3Q4 2031RimegepantMigraineNCT05156398

Phase 2Dec 31, 2031ElrantamabMultiple MyelomaNCT06483100

Phase 2Dec 31, 2031ZEN003694Ovarian Cancer, Peritoneal Cancer, Fallopian Tube CancerNCT05071937

Phase 3Q4 2031Gemtuzumab ozogamicinAcute Myeloid LeukaemiaNCT02724163

Phase 3Q1 2032AbrocitinibAtopic DermatitisNCT06807281

Phase 2Q4 2032ElranatamabMultiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)NCT06974786

Phase 3Q2 2033Omitted DoxorubicinLeukemia, Acute LymphoblasticNCT04307576

Phase 2Q4 2033Inotuzumab ozogamicinACUTE LYMPHOBLASTIC LEUKEMIANCT05748171

Phase 3Q2 2036ElranatamabMultiple Myeloma, Newly DiagnosedNCT06918002

Phase 3Q1 2040Hemophilia A, Hemophilia BNCT05568719

PFIZER INC

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Conferences

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research